One day, CAR T Cell therapy will become a routine treatment option to physicians.

Our mission is to advance CAR T Cell therapy by unlocking and sharing knowledge, facilitating collaboration, education and awareness, and building a network of experts. Ultimately, these will improve patient care and cure more patients from blood cancer.

Towards a cure for all blood disorders

One day, CAR T Cell therapy will become a routine treatment option to physicians.
Powered by:

“In the field of immunotherapy, chimeric-antigen-receptor therapy (CAR T) is one of the most promising and rapidly developing treatments. Many initiatives flourish, but before this treatment is available for many, problems need to be resolved and challenges have to be taken on.

We believe that by joining forces, we can help move this exciting development forward. Therefore, as a start, we bring together news, information and knowledge we have available in one place with the aim to share it in an easy way with all those interested in it. Together we can accelerate CAR T cell therapy in Europe!”

Pieter Sonneveld, former EHA President
Professor of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
About us

EHA is a non-governmental and not-for-profit membership organization guided by its mission to promote excellence in patient care, research and education in hematology. In pursuing this mission, EHA acts exclusively in the interest of hematology and its practitioners and is bound by core values of independence, integrity and transparency.

As a Common Good Organization, EHA’s profits, generated from its congress, are invested in other activities that serve the hematology community. The Board and Committee members contribute on a voluntary basis to the association’s work. EHA is an open networking organization. We cherish and
celebrate collaboration to share knowledge and experience and help hematology and hematologists achieve excellence in every part of the world.

We value sustainability, not only environmentally but especially in relationships and collaboration.


Read more
#1 - Research

“The development of donor cell therapy instead of using the patient’s own cells might be a way to reduce time for preparing the treatment and reduce costs at the same time.”

Professor Marie José Kersten, EHA Task Force Immunotherapy
Hematology Department Head, Academic Medical Center, Amsterdam, The Netherlands
#2 - Regulations

“To enable uptake of approved CAR T cell therapies, we need harmonized guidance at EU level. For example, guidelines for the qualification of hospitals and training of multidisciplinary teams on the basis of a European curriculum.”

Professor Christine Chomienne, EHA Task Force Immunotherapy
Director of Research and Innovation at the French National Cancer Institute (INCa), Paris, France

CAR T cell therapy uses a patient's own re-engineered T cells to attack cancer cells.

It is a new and unique way to treat cancer, which essentially makes a patient’s own immune system fight cancer cells. It has already proven to change the outlook for some children and adults with otherwise incurable blood cancers. The recent approvals of the first CAR T cell treatments in Europe provide a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment and its side effects. Patients, physicians, nurses, hospitals and the whole health care system need to learn how to select the right patients, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T cell therapy.


Selected from the CAR T Cell Net news platform

Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.

Chimeric antigen receptor T-cell (CAR T-cell) therapy targeting CD19 is highly effective in B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma, with many patients achieving a durable remission.


Are CAR-T therapies living up to their hype?

A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants.


The Promise and Price of Cellular Therapies

'New “living drugs”—made from a patient’s own cells—can cure once incurable cancers. But can we afford them?' is an interesting article CAR-T therapy by Siddhartha Mukherjee in the New Yorker.



EHA is one of the largest international, independent providers of hematological knowledge. To harmonize hematology knowledge, EHA offers a comprehensive and integral curriculum which forms the basis of its Medical Education Program, through which professionals acquire state-of-the-art knowledge. To ensure high-quality resources and make sure material is original, up-to-date and relevant, all EHA learning tools are peer-reviewed by designated hematology professionals.

For the rapidly developing field of CART cell therapy, different e-courses, learning programs and preceptorships are in preparation. The learning tools created by hematology professionals will be available on het EHA Campus, the online learning platform for hematology professionals.

Learn more


EHA aims to foster science and spread knowledge in basic, translational and clinical research in hematology in Europe. The EHA Roadmap for European Hematology Research identifies priorities and needs across the different areas of hematology. A fundamental component of EHA initiatives for research in hematology are the 23 EHA Scientific Working Groups and their regular EHA-SWG Scientific Meetings 

Learn more


By engaging with EU institutions and other relevant stakeholders, EHA strives to achieve more and better research funding opportunities, improve regulations, increase the availability and affordability of medicines, and harmonize education and training of hematologists across Europe.

Here you will find the relevant policy and advocacy initiatives of EHA on CAR T Cell therapy.

Learn more